By Turna Ray
Researchers in the European Union are keeping a close eye on the outcome of the American Civil Liberties Union/Public Patent Foundation's anti-gene patenting case against Myriad, according to one of the main instigators of an opposition effort that resulted in narrowing the claims of a key European BRCA patent two years ago.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
